Telix Pharmaceuticals Limited

7 hours ago · seekingalpha.com

Telix Pharmaceuticals Limited (TLX) M&A Call Transcript

1 day ago · globenewswire.com

MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE (“ITM”), a global leader in radioisotope production and radiopharmaceutical development.

1 day ago · reuters.com

Australia's Telix Pharmaceuticals ​said on ‌Monday it has ​agreed to ​acquire Germany-based ITM ⁠Isotope ​Technologies Munich SE ​for about $1.65 billion on a ​cash- ​and debt-free basis.

5 days ago · seekingalpha.com

Telix Pharmaceuticals is maintained at a “Buy” rating, supported by FDA approval of PIXCLARA and robust pipeline progress in oncology diagnostics and therapeutics. The company achieved the first FDA-approved FET-PET imaging agent for glioma, with potential label expansion into brain metastases via a phase 3 study. Phase 3 programs for TLX250-Tx in ccRCC and TLX591-Tx in mCRPC are advancing, with FDA alignment and promising safety/pharmacokinetic data supporting further development.

8 days ago · benzinga.com

On Monday, the U.S. Food and Drug Administration (FDA) approved Pixclara (floretyrosine F18), an amino acid positron emission tomography (PET) imaging agent created by Telix Pharmaceuticals Limited (NASDAQ:TLX) to diagnose brain cancer.

8 days ago · globenewswire.com

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

21 days ago · globenewswire.com

MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga68 gozetotide injection) for prostate cancer imaging in the pre-biopsy setting. Telix has also aligned with the United States (U.S.) Food and Drug Administration (FDA) on a New Drug Application (NDA) pathway for BiPASS that, if approved, would support reimbursement as a new product and broaden patient access.

22 days ago · globenewswire.com

MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appointed Chair of the Board, effective immediately.

29 days ago · seekingalpha.com

Telix Pharmaceuticals has rebounded strongly, reaching profitability and guiding FY2026 revenue to $950–$970 million, driven by precision medicine sales. Key catalysts include imminent FDA decisions for TLX101-Px (brain tumor imaging) and resubmission plans for TLX250-Px (kidney cancer imaging). TLX's radiopharmaceutical pipeline advances with pivotal studies in prostate cancer diagnostics and therapeutics, supported by robust financials and a recent $600 million convertible bond raise.

1 month ago · seekingalpha.com

Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript